Ginkgo bioworks reports fourth quarter and full year 2023 financial results

$251 million of total revenue in 2023 $139 million in cell engineering services revenue, representing 31% growth over 2022 78 new cell programs added in 2023, representing 32% growth over 2022 and continued penetration in biopharma year-end cash balance of nearly $950 million provides meaningful multi-year runway as we drive towards profitability and begin recognizing benefits from improved platform efficiency boston , feb. 29, 2024 /prnewswire/ -- ginkgo bioworks holdings, inc. (nyse: dna, "ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended december 31, 2023. the update, including a webcast slide presentation and supplemental financial information, will be available at investors.ginkgobioworks.com.
DNA Ratings Summary
DNA Quant Ranking